Comparison of the immunohistochemical properties of the tumor cells and of the background between NLPHL, NLPHL with T-cell/histiocyte rich-like nodules, and T/HRBCL
Diagnosis . | NLPHL, 53 cases . | P . | NLPHL with T-cell/histiocyte-rich nodules, 17 cases . | P . | T/HRBCL, 35 cases . | P, NLPHL vs T/HRBCL . |
|---|---|---|---|---|---|---|
| Tumor cells | ||||||
| CD20, % | 100 | NS | 100 | NS | 100 | NS |
| CD79a, % | 8 | .03 | 29 | NS | 40 | < .001 |
| J chain, % | 52 | NS | 29 | NS | 46 | NS |
| CD30, % | 6 | NS | 6 | NS | 9 | NS |
| EMA, % | 29 | NS | 35 | NS | 30 | NS |
| BCL-2, % | 4 | NS | 0 | .005 | 40 | < .001 |
| ICSAT, % | 98 | NS | 100 | NS | 94 | NS |
| PU.1, % | 86 | .005 | 53 | NS | 54 | < .001 |
| Background | ||||||
| CD20 | < 1:20 | NS | 1:2.7 | NS | > 1:1.5 | NS |
| CD3 rosettes, % | 89 | NS | 88 | .02 | 57 | < .001 |
| CD4 rosettes, % | 48 | NS | 29 | NS | 15 | .02 |
| CD8 rosettes, % | 0 | NS | 0 | NS | 6 | NS |
| CD57 rosettes, % | 37 | NS | 31 | .018 | 6 | < .001 |
| CD68, % | 66 | .0029 | 94 | NS | 97 | < .001 |
| TIA-1, % | 47 | .034 | 76 | .032 | 86 | < .001 |
| Granzyme B, % | 28 | NS | 35 | .001 | 85 | < .001 |
Diagnosis . | NLPHL, 53 cases . | P . | NLPHL with T-cell/histiocyte-rich nodules, 17 cases . | P . | T/HRBCL, 35 cases . | P, NLPHL vs T/HRBCL . |
|---|---|---|---|---|---|---|
| Tumor cells | ||||||
| CD20, % | 100 | NS | 100 | NS | 100 | NS |
| CD79a, % | 8 | .03 | 29 | NS | 40 | < .001 |
| J chain, % | 52 | NS | 29 | NS | 46 | NS |
| CD30, % | 6 | NS | 6 | NS | 9 | NS |
| EMA, % | 29 | NS | 35 | NS | 30 | NS |
| BCL-2, % | 4 | NS | 0 | .005 | 40 | < .001 |
| ICSAT, % | 98 | NS | 100 | NS | 94 | NS |
| PU.1, % | 86 | .005 | 53 | NS | 54 | < .001 |
| Background | ||||||
| CD20 | < 1:20 | NS | 1:2.7 | NS | > 1:1.5 | NS |
| CD3 rosettes, % | 89 | NS | 88 | .02 | 57 | < .001 |
| CD4 rosettes, % | 48 | NS | 29 | NS | 15 | .02 |
| CD8 rosettes, % | 0 | NS | 0 | NS | 6 | NS |
| CD57 rosettes, % | 37 | NS | 31 | .018 | 6 | < .001 |
| CD68, % | 66 | .0029 | 94 | NS | 97 | < .001 |
| TIA-1, % | 47 | .034 | 76 | .032 | 86 | < .001 |
| Granzyme B, % | 28 | NS | 35 | .001 | 85 | < .001 |
Markers for tumor cells are given as the percentage of cases expressing the respective antigen in more than a few cells. The rows under “Background” give the percentage of cells/rosettes staining with the respective antibody more than occasionally. The CD20 ratio is the ratio of tumor cells to reactive small B cells. For CD3, CD4, CD8, and CD57, rosettes were evaluated to achieve data of higher reliability. Nominal P values are given only when the difference is statistically significant.
NS indicates not significant.